HER2 positive breast cancer
Not recruitingStudy on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy
Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy
- Disease:HER2 positive breast cancer
- Substances:AtezolizumabTrastuzumab+1
Poland- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:F. Hoffmann-La Roche AG








